A plausible mechanism for pyrimethamine-induced cancer selectivity in HCC is shown in Fig. 6b, which is mediated by lysosomal modification (increases in cathepsin B and cleaved caspase-3) and DNA damage. The gene discussed is CTSB; the disease is hepatocellular carcinoma.